Chiba University and UC San Diego, collaborators in the new Program in Mucosal Immunology, Allergy and Vaccine Development based at UC San Diego, are hosting the inaugural Symposium in Mucosal Immunology and Immunization on February 21-22, 2017, at UC San Diego.
Co-Directors of the program are Peter Ernst, DVM, PhD, Professor of Pathology and Medicine at UC San Diego School of Medicine, and Hiroshi Kiyono, DDS, PhD, Professor, University of Tokyo and Chiba University.
Previous studies identified the Hippo pathway kinases LATS1/2 as a tumor suppressor, but new research led by University of California San Diego School of Medicine scientists reveals a surprising role for these enzymes in subduing cancer immunity. The findings, published in Cell on December 1, could have a clinical role in improving efficiency of immunotherapy drugs. … Read the Full Story from the UC San Diego Newsroom
In mouse models and patient cells, anti-CD98 antibody disrupts interactions between leukemia cells and surrounding blood vessels, inhibiting cancer’s growth —
Acute myeloid leukemia (AML) is an aggressive cancer known for drug resistance and relapse. In an effort to uncover new treatment strategies, researchers at University of California San Diego School of Medicine and Moores Cancer Center discovered that a cell surface molecule known as CD98 promotes AML. … Read the Full Story from the UC San Diego Newsroom
Dr. Mark Ginsberg
Department of Medicine Professor Mark H. Ginsberg, MD, co-directed the study with Tannishtha Reya, PhD, professor of pharmacology.
Dr. Ginsberg is Professor of Medicine in the Division of Rheumatology, Allergy & Immunology at UC San Diego School of Medicine and Moores Cancer Center.
Rikki Rockett, drummer for the band Poison, got the best news of his life last week: his cancer is gone. Rockett was diagnosed with oral cancer more than a year ago. Several months ago, he came to Moores Cancer Center at UC San Diego Health, where he underwent experimental cancer immunotherapy, which has now eradicated the tumor.
UC San Diego researchers leading efforts to find turning point to virus —
On April 18, 1947, a monkey in Uganda’s Zika Forest fell ill with a fever of 103 degrees Fahrenheit, 4 degrees higher than normal. “Rhesus No. 766” was part of a yellow fever virus study. Scientists took a blood sample. They conducted tests. The rhesus monkey had been stricken by something unknown. In time, the revealed virus would be named after the place where it was first discovered.
But for decades to follow, the Zika virus would garner only sporadic and limited scientific attention. It was determined that the virus could infect humans, but symptoms—if there were any—appeared to be mild (fever, joint pain, rash) and passing. Zika wasn’t deemed a significant human health threat until a major outbreak occurred in the Yap Islands north of Australia in 2007, followed by another in French Polynesia in 2013. For the first time, the Zika virus was associated with serious symptoms, including life-threatening neurological disorders. … Read the Full Story from the UC San Diego Newsroom
Chiba University and UC San Diego launch $2 million collaborative partnership —
Immunology – and the idea that many diseases can best be addressed by boosting the body’s own immune response – is one of the hottest areas in medical research and clinical treatment. University of California San Diego School of Medicine and Chiba University School of Medicine in Japan have announced a new collaborative research center to investigate the most promising aspects of immunology, especially the area of mucosal immunology, and to speed development of clinical applications. … Read the Full Story from the UC San Diego Newsroom
Dr. Peter Ernst
Dr. Peter Ernst is co-directing the Chiba University-UC San Diego Immunology Initiative and associated research center.